Cargando…
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Nature Singapore
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700611/ https://www.ncbi.nlm.nih.gov/pubmed/36243793 http://dx.doi.org/10.1007/s10147-022-02252-3 |
| _version_ | 1784839348430045184 |
|---|---|
| author | Sugawara, Shunichi Kondo, Masashi Yokoyama, Toshihide Kumagai, Toru Nishio, Makoto Goto, Koichi Nakagawa, Kazuhiko Seto, Takashi Yamamoto, Nobuyuki Kudou, Kentarou Asato, Takayuki Zhang, Pingkuan Ohe, Yuichiro |
| author_facet | Sugawara, Shunichi Kondo, Masashi Yokoyama, Toshihide Kumagai, Toru Nishio, Makoto Goto, Koichi Nakagawa, Kazuhiko Seto, Takashi Yamamoto, Nobuyuki Kudou, Kentarou Asato, Takayuki Zhang, Pingkuan Ohe, Yuichiro |
| author_sort | Sugawara, Shunichi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9700611 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Nature Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97006112022-11-27 Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study Sugawara, Shunichi Kondo, Masashi Yokoyama, Toshihide Kumagai, Toru Nishio, Makoto Goto, Koichi Nakagawa, Kazuhiko Seto, Takashi Yamamoto, Nobuyuki Kudou, Kentarou Asato, Takayuki Zhang, Pingkuan Ohe, Yuichiro Int J Clin Oncol Correction Springer Nature Singapore 2022-10-16 2022 /pmc/articles/PMC9700611/ /pubmed/36243793 http://dx.doi.org/10.1007/s10147-022-02252-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Sugawara, Shunichi Kondo, Masashi Yokoyama, Toshihide Kumagai, Toru Nishio, Makoto Goto, Koichi Nakagawa, Kazuhiko Seto, Takashi Yamamoto, Nobuyuki Kudou, Kentarou Asato, Takayuki Zhang, Pingkuan Ohe, Yuichiro Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study |
| title | Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study |
| title_full | Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study |
| title_fullStr | Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study |
| title_full_unstemmed | Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study |
| title_short | Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study |
| title_sort | correction to: brigatinib in japanese patients with tyrosine kinase inhibitor-naive alk-positive non-small cell lung cancer: first results from the phase 2 j-alta study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700611/ https://www.ncbi.nlm.nih.gov/pubmed/36243793 http://dx.doi.org/10.1007/s10147-022-02252-3 |
| work_keys_str_mv | AT sugawarashunichi correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT kondomasashi correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT yokoyamatoshihide correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT kumagaitoru correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT nishiomakoto correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT gotokoichi correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT nakagawakazuhiko correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT setotakashi correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT yamamotonobuyuki correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT kudoukentarou correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT asatotakayuki correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT zhangpingkuan correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy AT oheyuichiro correctiontobrigatinibinjapanesepatientswithtyrosinekinaseinhibitornaivealkpositivenonsmallcelllungcancerfirstresultsfromthephase2jaltastudy |